14:28 ET -- Moderna Inc. is one of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Early Wednesday, Merck said it will exercize an option to collaborate with Moderna on a personalized cancer vaccine, where it will pay Moderna $250 million for the joint development and future commercialization of the vaccine. Later Wednesday morning, Moderna said it has received FDA authorization for its Omicron-targeting bivalent Covid-19 booster vaccine in children and teens 6 to 17 years of age. Dow Jones & Co. owns Factiva. (susan.solan@wsj.com)

 

(END) Dow Jones Newswires

October 12, 2022 14:43 ET (18:43 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2023 to Feb 2023 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Feb 2022 to Feb 2023 Click Here for more Moderna Charts.